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Abstract Mutations in the phosphate-regulating endo-
peptidase homolog, X-linked, gene (PHEX), which
encodes a zinc-dependent endopeptidase that is involved in
bone mineralization and renal phosphate reabsorption,
cause the most common form of hypophosphatemic rickets,
X-linked hypophosphatemic rickets (XLH). The distribu-
tion of PHEX mutations is extensive, but few mutations
have been identiﬁed in Chinese with XLH. We extracted
genomic DNA and total RNA from leukocytes obtained
from nine unrelated Chinese subjects (three males and six
females, age range 11–36 years) who were living in Tai-
wan. The PHEX gene was ampliﬁed from DNA by PCR,
and the amplicons were directly sequenced. Expression
studies were performed by reverse-transcription PCR of
leukocyte RNA. Serum levels of FGF23 were signiﬁcantly
greater in the patients than in normal subjects (mean
69.4 ± 18.8 vs. 27.2 ± 8.4 pg/mL, P\0.005), and eight
of the nine patients had elevated levels of FGF23. Germ-
line mutations in the PHEX gene were identiﬁed in ﬁve of 9
patients, including novel c.1843 delA, donor splice site
mutations c.663?2delT and c.1899?2T[A, and two pre-
viously reported missense mutations, p.C733Y and
p.G579R. These data extend the spectrum of mutations in
the PHEX gene in Han Chinese and conﬁrm variability for
XLH in Taiwan.
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Although acquired vitamin D deﬁciency is the principal
cause of rickets worldwide, rickets (and osteomalacia) can
also arise in patients with defects that perturb vitamin D
metabolism or responsiveness or with conditions that cause
hypophosphatemia. Phosphate homeostasis is principally
controlled by changes in the tubular reabsorption of
phosphate, which is regulated, directly or indirectly, by
PTH, phosphatonins such as FGF23, and 1,25(OH)2D.
Thus, hypophosphatemia and hypophosphatemic rickets
most commonly occur in patients who have conditions that
depress renal tubular phosphate transport. A variety of
acquired and genetic disorders have been described in
which decreased renal tubular phosphate reabsorption leads
to the development of hypophosphatemic rickets. An
acquired form of hypophosphatemia occurs in patients with
ﬁbrous dysplasia or mesenchymal tumors that overexpress
FGF23, a phosphatonin that reduces expression of the
NaPi2a and NaPi2c sodium–phosphate cotransporters in
renal proximal tubular cells and impairs synthesis of
1,25(OH)2D[ 1, 2]. In addition, at least ﬁve inherited forms
of hypophosphatemic rickets have now been characterized:
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307810) is caused by mutations in the PHEX gene located
at Xp22.1 [3], autosomal dominant hypophosphatemic
rickets (MIM 193100) is caused by mutations in the
FGF23 gene [4], autosomal recessive hypophosphatemic
rickets (MIM 600980) is caused by mutations in the DMP1
[5, 6]o rENPP1 [7, 8] gene, and autosomal recessive
hypophosphatemic rickets with hypercalciuria (HHRH) is
caused by mutations in SLC34A3 encoding the NaPi-IIc
renal sodium–phosphate cotransporter [9–11]. XLH is the
most prevalent form of inherited rickets in humans, with an
incidence of 1 in 20,000 individuals [12, 13]. It is a dom-
inant disorder characterized by hypophosphatemia sec-
ondary to renal phosphate wasting, abnormal regulation of
renal metabolism of vitamin D, rickets and osteomalacia,
growth failure, and resistance to vitamin D therapy.
Despite marked hypophosphatemia, these patients seldom
present with muscle weakness [13–15].
The PHEX gene encompasses 22 exons and encodes a
749-amino acid protein with signiﬁcant structural homol-
ogy to members of the type II integral membrane zinc-
dependent endopeptidase family, with short N-terminal
cytoplasmic domains, a single transmembrane domain, and
a long extracellular domain [3]. Defective PHEX function
is associated with increased serum concentrations of the
phosphatonin FGF23, which likely accounts for the meta-
bolic defects in hypophosphatemic rickets. More than 250
mutations in the PHEX gene have been identiﬁed to date in
patients with XLH and are catalogued in a locus-speciﬁc
database [16]( www.phexdb.mcgill.ca). The mutations,
which are scattered throughout the gene, include deletions,
splice junction and frameshift mutations, duplications,
insertions, and missense and nonsense mutations and are
consistent with loss of function of the PHEX protein. XLH
due to unique mutations in PHEX has been reported in
subjects of East Asian ethnicity including Japanese, Kor-
ean, and Chinese living in China and Taiwan [17–25].
Mutational founder effects for a variety of genetic disor-
ders, as well as haplotype sharing in only a small chro-
mosomal interval, have been found in East Asians that are
not replicated in Caucasians, suggesting that speciﬁc
mutations are ancient and occurred after the divergence of
East Asians and Caucasians. In this study, we sought to
identify PHEX gene mutations in Chinese patients with
hypophosphatemic rickets who are living in Taiwan.
Patients and Methods
Patients
We studied nine unrelated Chinese subjects (three males
and six females, age range 11–36 years) with clinical and
biochemical manifestations of early-onset or congenital
hypophosphatemic rickets, including hypophosphatemia,
short stature, and lower extremity deformities (Table 1).
There were three familial (cases 1, 2, and 5) that showed
dominant transmission of rickets and six sporadic cases. At
the time of these studies, all affected subjects except pro-
band 1 and his sister and proband 2 and her brother were
receiving treatment with an active form of vitamin D plus
phosphate. This study was approved by the institutional
review board of the Taipei Veterans General Hospital, and
informed consent was obtained from each individual.
Serum Measurements
Serum concentrations of intact FGF23 were measured
using a two-site enzyme-linked immunosorbent assay
(FGF23 ELISA Kit; Kainos, Tokyo, Japan) according to
the manufacturer’s recommendations. All samples were
assayed at the same time in the same assay. Circulating
levels of intact FGF-23 were measured in serum from nine
patients, two siblings, and 11 age- and sex-matched normal
individuals. Serum 1,25(OH)2D levels were measured with
RIA (DiaSorin, Stillwater, MN). The TRP was calculated
using the standard, formula and TmP/GFR was determined
using the nomogram of Bijvoet [12, 26, 27].
PHEX Mutational Analysis
Genomic DNA was isolated from EDTA-preserved whole
blood using the GFX Genomic Blood DNA puriﬁcation kit
(AmershamBiosciences,Piscataway,NJ).Twenty-twopairs
of PHEX-speciﬁc primers [22] were used for PCR ampliﬁ-
cation of the coding exons and adjoining splice sites in a
25-lLreactioncontaining200 ngofgenomicDNA,2.0 mM
MgCl2, 0.2 mM of each dNTP, 0.15 M of each primer, 19
reactionbuffer,and1unitofFastStartTaqDNApolymerase
(Roche, Indianapolis, IN). The DNA sequences of both
strands were determined by Taq polymerase cycle
sequencing using ﬂuorescence-labeled dideoxyterminators
(BigDye Terminator V3.1 Cycle Sequencing Kits; Applied
Biosystems, Foster City, CA) and resolved on an automated
detection system (ABI 377-36 sequencer, Applied Biosys-
tems). Mutations are reported according to the guidelines of
the Human Genome Variation Society; based on the cDNA
sequence, ?1 is the A of the ATG start codon [28].
Novel mutations were deﬁned by their absence from the
Human Gene Mutation Database (http://www.uwcm.ac.
uk/uwcm/mg/hgmd0.html) and from mutations previously
reported in the PHEX-speciﬁc database [16]( www.
phexdb.mcgill.ca). The functional consequences of novel
splice variants were predicted with the NNSPLICE 0.9
automated splice site analysis program on the web (http://
www.fruitﬂy.org/seq_tools/splice.html)[ 29].
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123RT-PCR
TotalRNAwasextractedfromperipheralwholebloodusing
a QIAamp RNA Blood Mini Kit (Qiagen, Hilden, Ger-
many). First-strand cDNA was generated with SUPER-
SCRIPT II reverse transcriptase (Invitrogen, Carlsbad, CA)
using an oligo(dT)12–18 primer and subsequentlyused as a
template for PCR. For proband 2, the forward primer
(ggtctcttaagtctccaagc) was located in exon 2 and the reverse
primer (tttgttgtacatggcctcgc) was located in exon 8. PCR
productsoffemalesubjectswereclonedintopGEM-Tvector
(Promega, Madison, WI), and 10 clones were selected for
sequence analysis (Applied Biosystems). For proband 3, the
forward primer (atccgacgactgtcaatgcc) was located in exon
15 and the reverse primer (ttggacttgttctcgggcag) in exon 21.
The products of RT-PCRs for cases 2 and 3 were electro-
phoresed on 3% agarose gel and stained with ethidium bro-
mide. The identity of the amplicons was conﬁrmed by
nucleotide sequence analysis.
Statistical Analysis
All data are expressed as the mean ± SD, and comparison
between groups was calculated using unpaired Student’s
t-tests. Linear regression was used to compare phenotypic
features and genotypes. P\0.05 was considered signiﬁ-
cant. GraphPad InStat, version 3.06 (GraphPad, San Diego,
CA), was used to perform statistical analyses.
Results
Clinical Features
The clinical, molecular, and biochemical data for all nine
patients are shown in Table 1. Patients 4 and 5 had expe-
rienced multiple fractures of the lower extremities. The
mean serum FGF23 level was signiﬁcantly higher in
patients than in normal subjects (69.4 ± 18.8 vs. 27.2 ±
8.4 pg/mL, P\0.005) and frankly elevated in eight of
nine patients (Table 1). At the time of sampling, probands
1 and 2 were not taking either calcitriol or phosphate; other
subjects either were taking low doses of calcitriol and
phosphate or were poorly compliant.
Mutations of the PHEX Gene
DNA analysis of the entire coding region together with
the associated splice sites and 50 and 30 untranslated
regions of the PHEX gene disclosed mutations in ﬁve of
Table 1 Clinical, biochemical, and molecular data for all patients
Proband
a PHEX mutation Sex Age
(years)
Height
(cm)
Z scores for
height
Weight
(kg)
S.Ca
(mmol/L)
1 nt 1843 del A, exon 18 M 29 150 -3.69 50 2.40
2 IVS5 ? 2 del t, intron 5 F 20 133 -5.00 47 2.40
3 IVS18?2t ?a, intron 18 M 30 148 -4.03 53 2.40
4 p.C733Y, exon 22 F 33 144 -2.92 62 2.27
5 p.G579R, exon 17 F 36 142 -3.30 42 2.35
6 N F 15 143 -2.76 49 2.47
7 N F 30 136 -4.43 46 2.35
8 N F 16 142 -3.15 43 2.32
9 N M 11 128 -2.23 34 2.50
Normal 2.15–2.60
Proband
a U.Ca/Cr
(mmol/L)
S.Phos
(mmol/L)
TRP TmP/GFR
(mmol/L)
1,25 (OH)2D
(pmol/L)
FGF23
(pg/mL)
1 0.23 0.52 0.90 0.46 85 55.8
2 0.17 0.61 0.82 0.50 95 55.8
3 0.12 0.39 0.54 0.20 48 88.8
4 0.03 0.68 0.80 0.53 34 63.3
5 0.14 0.77 0.78 0.47 235 50.1
6 0.22 0.87 0.90 0.77 151 55.8
7 0.04 0.61 0.65 0.39 83 85.0
8 0.01 0.81 0.68 0.54 123 104.3
9 ND 0.81 0.81 0.65 86 89.5
Normal \0.62 0.8–1.45 [0.90 0.80–1.35 39–102 18.6–50.8
a Cases 1, 2, and 5 were familial
N no detectable mutation, ND not done
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123the 9 patients we studied (Table 1, Fig. 1). Patient 1 was
hemizygous for a single nucleotide deletion (c.1843 del
A) in exon 18 of the PHEX gene, resulting in a frameshift
and early translational termination that is predicted to
produce a protein that is truncated at amino acid residue
617. Patient 2 was heterozygous for a donor site mutation
(c.663 ? 2delT) in intron 5. RT-PCR of RNA from
patient 2 produced two amplicons, one that corresponded
to the expected size of 771 bp and a shorter amplicon of
694 bp (Fig. 1b). Analysis of this mutation by NNS-
PLICE 0.9 [29] predicted aberrant splicing of the PHEX
mRNA, which was conﬁrmed by RT-PCR of leukocyte
RNA and nucleotide sequence analysis, which conﬁrmed
the usage of an alternative 50-splice site in exon 5 that
was located 77 nucleotides upstream of the normal donor
splice site (Fig. 1). Patient 3 was hemizygous for a donor
site transversion (c.1899?2T[A) in intron 18 that also
was predicted to result in aberrant splicing of the PHEX
mRNA. RT-PCR of leukocyte RNA from this patient
revealed a PHEX cDNA that utilized an alternative 50-
splice site that is 131 nucleotides upstream of the normal
donor site and results in skipping of exon 18 (Fig. 1c).
The amplicon of RT-PCR corresponding to wild-type
cDNA was 521 bp and the mutant transcript was 390 bp
(Fig. 1c). These changes are predicted to result in a
frameshift and a premature termination codon. None of
Normal control c.1843 delA
Hemizygous
Normal control c.663+2 delT
Heterozygous
Normal control c.1899+2 T A
Hemizygous
(b) (a)
(c)
Normal allele: 771bp   
Mutant allele:  694bp  
Normal allele: 521 bp   
Mutant allele: 390 bp   
C733Y
Heterozygous
G 
T         T
A
Normal control
(d)
G579R
Heterozygous
G 
G   A
A 
Normal control
(e)
Fig. 1 Molecular analysis of PHEX. a Proband 1 had a c.1843 delA
mutation in his copy of the PHEX gene. b Proband 2 was
heterozygous for c.663?2delT, resulting in alternative splicing of
mRNA from this allele. The amplicons generated by RT-PCR of RNA
from a normal subject and the patient are shown and indicate that the
patient had a smaller band (694 bp) than expected (771 bp) for the
wild-type allele. The RT-PCR product of this patient was sequenced,
and the 50-splice site of intron 5 was shifted 77 nucleotides upstream
in exon 5. c Patient 3 was hemizygous for the c.1899?2T[A
mutation that resulted in an abnormally spliced mRNA in which the
50-donor splice site of intron 18 was shifted 131 nucleotides upstream
of the native donor splice site, resulting in skipping of exon 18. The
amplicon corresponding to wild-type cDNA is 521 bp, and the
corresponding mutant amplicon is 390 bp. d Patient 4 had a C733Y
missense mutation (TGT ? TAT) in codon 733 of exon 22. e Patient
5 had a G579R missense mutation (GGA ? AGA) in codon 579 of
exon 17
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123these sequence changes was present in genomic DNA
from 50 unrelated subjects.
Patients 4 (C733Y) and 5 (G579R) were heterozygous
for missense mutations that have been previously described
[30, 31].
Patients 1, 2, and 5 have familial hypophosphatemic
rickets.Theaffectedbrotherandmotherofproband2hadthe
same genotype, and all of them had severe genu varum and
short stature. Proband 2 had severe genu varum and had
undergoneosteotomyofthelowerextremitiesfourtimes.All
of the clinically affected relatives of proband 5 carried the
same mutation and presented with genu varum and short
stature. Regrettably, neither of the two affected family
members of proband 1 agreed to participate in this study.
There was no relationship between height SD and
presence or absence of a PHEX mutation, nor were there
any relationships between type of mutation and height SD,
serum concentration of FGF23, and serum phosphate lev-
els. Moreover, we found no evidence for a relationship
between serum concentrations of FGF23 and serum levels
of phosphate or calcitriol.
Discussion
We analyzed the PHEX gene in nine unrelated Chinese
subjects with early-onset hypophosphatemic rickets,
including three patients with familial rickets and six
patients with sporadic rickets. Our mutation detection rates
in the PHEX gene were 100% in familial cases and 33% in
sporadic cases, which are similar to the results of most
previous studies in which the mutation detection rates
ranged 51–86% in familial cases and 22–57% in sporadic
cases [18, 30–34]. One notable exception is a single study
from Finland, in which the mutation detection rate was
100% for familial cases and 93% for sporadic cases [35].
The lower mutation detection rate in apparently sporadic
cases might reﬂect nongenetic causes of renal phosphatu-
ria, autosomal recessive forms of hypophosphatemic rick-
ets due to mutations in the DMP1 [5, 6]o rENPP1 [7, 8]
gene, or the presence of de novo mutations in the FGF23
gene [4].
Our work raises several points that are worth noting.
First, all of the PHEX mutations that we identiﬁed in this
study were different from the mutations that have been
previously described in Chinese patients with XLH [19]
(Fig. 2), indicating that there is signiﬁcant variability in
PHEX mutations in this population. Second, the mutations
in the coding exons of PHEX were found in the 30 end of
the gene, which is consistent with the results of previous
studies [36, 37] and mutations entered in PHEXdb [16],
which suggests that this region might encode for a critical
region of the PHEX protein. Third, the two donor splice
site mutations both resulted in an aberrant 50-splice site. As
is typical of mutations at donor or acceptor sites, the two
mutations that we identiﬁed utilized upstream cryptic
splice sites that in one case resulted in skipping of the
upstream exon. Mutations affecting splice sites are com-
mon in human genetic disease and account for 10–15% of
gene mutations. The majority of these are single-point
mutations affecting the conserved bases at the donor or
acceptor splice sites. A study of more than 100 splice-site
mutations [38, 39] showed that point mutations affecting
the 50 donor splice site were more common than those at
the 30 acceptor site (62% vs. 26%). At the 50 donor splice
site, mutations affecting the G residue at position ?1 are
the most common, followed by mutations at position ?5.
Mutations at these two positions are thought to signiﬁ-
cantly reduce the pairing of the donor splice site with the
complementary site in the small nuclear ribonucleoprotein
particle U1snRNP, which is one of the ﬁrst steps in the
complex process of mRNA splicing [40, 41].
Lastly, we found elevated serum levels of intact FGF23
in eight of nine patients with hypophosphatemic rickets.
6789 45 3 2 2 2 1 2 0 2 9 1 8 1 7 1 6 1 5 1 4 1 3 1 2 1 1 1 0 1 1
c.264.delG
p.W88X
c.1673.C>G
p.P558A
c.1809.G>A
p.W603X
Xia et al.17
c.670.C>T
p.Q224X
c.2090.delGA
frameshift
Chou et al.14
c.617.T>G
p.L206W
Lo et al.15
c.1826.delAAAAG
p.E609X
c.1843.delA
p.M618X
c.2198.G>A
p.C733Y
c.1735.G>A
p.G579R
c.1899+2.T>A c.663+2.delT
Jap et al.  
c.1699.C>T
p.R567X
Su et al.16
Fig. 2 The distribution of PHEX gene mutations among Chinese with XLH is shown. Mutations in exon 18, in which the zinc-binding domain is
located, are the most common and account for 30% (4/13) of PHEX mutations in Chinese subjects
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FGF23 and hypophosphatemia in subjects with XLH and
other disorders characterized by hypophosphatemia [2, 42–
44]. Recent studies show that most subjects with XLH
demonstrate increases in serum FGF23 in response to
treatment with calcitriol and phosphate, with signiﬁcant
and nonsigniﬁcant positive associations with daily phos-
phate and calcitriol doses, respectively [45]. However, the
relatively low doses of calcitriol and phosphorus used by
the mostly adult subjects in our study, as well as generally
poor compliance in our population, did not permit us to
identify similar associations. Moreover, the cross-sectional
design of our study makes it very difﬁcult to determine if
an association or a lack of such is caused by differences in
treatment or by primary differences in the phenotype.
The sodium–phosphate cotransporters NaPi-IIc and
NaPi-IIa are coexpressed in the renal brush border mem-
brane of the proximal tubule, where most ﬁltered phosphate
is reabsorbed. NaPi-IIa and NaPi-IIc are both regulated by
PTH, FGF23, and dietary phosphate; PTH and FGF23, in
response to elevated levels of dietary and serum phos-
phorus, decrease the abundance of cotransporters at the cell
membrane and thereby reduce the tubular reabsorption of
phosphorus from the glomerular ﬁltrate [9, 46, 47]. Serum
levels of FGF23 are inappropriately normal or elevated in
XLH and other forms of hypophosphatemic rickets [1, 2]
except ADHR [11, 48].
A limitation of our study is the small sample size, which
may have restricted our ability to identify potential geno-
type–phenotype relationships between XLH and any of the
mutations that we identiﬁed. Although Holm et al. [31]
identiﬁed a trend between truncating mutations and more
severe skeletal disease in a familial group (P = 0.072), at
present no consensus has been reached regarding the cor-
relation between the disease phenotypes and PHEX muta-
tion locations, including those in this study [16, 18, 20, 22,
33, 37, 49, 50].
In conclusion, we have identiﬁed ﬁve mutations in the
PHEX gene in Han Chinese patients with XLH in Taiwan,
including three novel mutations. Our results, taken in the
context of prior studies of PHEX gene analyses in East
Asians, conﬁrm the notion that variable PHEX mutations
account for XLH in this population and extend the spec-
trum of PHEX gene defects that cause XLH.
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